Skip to main content
logo
Rapid Dose Therapeutics Corp. (CSE:DOSE)
Canada flag Canada · Delayed Price · Currency is CAD
0.1450
+0.0050 (3.57%)
Feb 9, 2026, 9:04 AM EST

Rapid Dose Therapeutics Income Statement

Millions CAD. Fiscal year is Mar - Feb.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '25 Feb '25 Feb '24 Feb '23 Feb '22 Feb '21
Revenue
2.782.091.020.721.750.76
Revenue Growth (YoY)
72.84%104.34%42.06%-59.00%131.98%644.05%
Cost of Revenue
1.380.910.460.360.410.13
Gross Profit
1.41.180.560.361.340.63
Selling, General & Admin
3.313.552.452.462.991.5
Research & Development
0.070.150.430.090.360.09
Operating Expenses
4.485.353.653.95.652.26
Operating Income
-3.08-4.17-3.09-3.54-4.3-1.63
Interest Expense
-1.29-1.23-0.66-0.26-0.13-0.14
Interest & Investment Income
----0-
Currency Exchange Gain (Loss)
----00.02-0.03
Other Non Operating Income (Expenses)
----0.01-
EBT Excluding Unusual Items
-4.37-5.4-3.75-3.81-4.4-1.81
Impairment of Goodwill
-----4.08-
Other Unusual Items
---0.56---
Pretax Income
-4.37-5.4-4.31-3.81-8.49-1.81
Net Income
-4.37-5.4-4.31-3.81-8.49-1.81
Net Income to Common
-4.37-5.4-4.31-3.81-8.49-1.81
Shares Outstanding (Basic)
13012510510310078
Shares Outstanding (Diluted)
13012510510310078
Shares Change (YoY)
7.98%18.68%1.50%3.19%28.83%2.23%
EPS (Basic)
-0.03-0.04-0.04-0.04-0.08-0.02
EPS (Diluted)
-0.03-0.04-0.04-0.04-0.08-0.02
Free Cash Flow
-0.87-1.15-2.29-0.86-3.04-1.63
Free Cash Flow Per Share
-0.01-0.01-0.02-0.01-0.03-0.02
Gross Margin
50.44%56.59%55.21%49.67%76.76%83.40%
Operating Margin
-110.68%-200.07%-302.45%-493.36%-245.55%-216.45%
Profit Margin
-157.17%-259.18%-422.03%-530.42%-484.47%-239.04%
Free Cash Flow Margin
-31.33%-55.27%-224.91%-120.27%-173.52%-216.20%
EBITDA
-2.65-3.95-2.75-3.2-3.82-1.25
EBITDA Margin
-95.17%-189.66%-269.93%--218.31%-165.21%
D&A For EBITDA
0.430.220.330.340.480.39
EBIT
-3.08-4.17-3.09-3.54-4.3-1.63
EBIT Margin
-110.68%-200.07%---245.55%-216.45%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.